Final answer:
Ezetimibe specifically blocks the cholesterol transporter NPC1L1, distinguishing it from other lipid-lowering drugs like statins and fibrates that work through different mechanisms.
Step-by-step explanation:
The cholesterol transporter NPC1L1 can be blocked by ezetimibe, which is a specific inhibitor of this transporter and acts by blocking the absorption of cholesterol in the gastrointestinal tract (GIT). Ezetimibe is different from other lipid-lowering drugs such as statins, which inhibit the enzyme HMG-CoA reductase, or fibric acid derivatives like clofibrate that may indirectly affect lipid levels but do not directly target NPC1L1. While ezetimibe works specifically on inhibiting cholesterol absorption, statins decrease cholesterol synthesis, and fibrates mainly affect the processing of lipids and lipoproteins.